Ah, got it. It also seems the more useful the drug, the higher the pressure for low cost generic licensing (though, then again, the larger the circulation). I

Ah, got it. It also seems the more useful the drug, the higher the pressure for low cost generic licensing (though, then again, the larger the circulation). I wonder if an X-Prize like model might work better here, with, e.g., individuals with genetic risk for a specific cancer "crowd funding" various grades of prizes, with the actual awarding of prizes, setting and advertising the prizes, being done by an organization/consortium that knows what they're doing.